Core IM | Internal Medicine Podcast #197 Hypercoagulability Part 2: 5 Pearls Segment
8 snips
Jan 7, 2026 Dive into the gray areas of VTE management! Discover how to determine anticoagulation duration for different types of clots. Learn about the significance of dose-reduced DOACs and what constitutes true DOAC failure. The discussion highlights antiphospholipid syndrome as a critical diagnosis that can shift treatment strategies. Explore detailed case examples involving cancer-related clots and travel-induced DVTs, emphasizing personalized risk assessments and practical takeaways in anticoagulation care.
AI Snips
Chapters
Transcript
Episode notes
Customize Anticoagulation Duration
- Assess anticoagulation duration by combining clot clinical risk (size/location) and recurrence risk.
- For high bleeding risk or older patients, finish full-dose then continue a dose-reduced DOAC for long-term prevention.
Distal DVTs Have Lower Recurrence
- Distal (below-knee) DVTs carry about half the recurrence risk of proximal DVTs.
- That lower risk supports shorter anticoagulation courses for low-risk unprovoked distal clots.
Use Dose‑Reduced DOACs For Secondary Prevention
- After an initial 3–6 month full-dose period, consider low-dose apixaban (2.5 mg BID) or rivaroxaban (10 mg daily) for indefinite secondary prevention.
- Trials (AMPLIFY-EXTEND, EINSTEIN-CHOICE, APICAT) show reduced recurrence with similar or lower bleeding versus full dose.